Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 476

The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.

Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?

Thota, Sreekanth, Rodrigues, Daniel A., Crans, Debbie C., Barreiro, Eliezer J.·2018·Journal of Medicinal Chemistry

Abstract

Metal based therapeutics are a precious class of drugs in oncology research that include examples of theranostic drugs, which are active in both diagnostic, specifically imaging, and therapeutics applications. Ruthenium compounds have shown selective bioactivity and the ability to overcome the resistance that platinum-based therapeutics face, making them effective oncotherapeutic competitors in rational drug invention approaches. The development of antineoplastic ruthenium therapeutics is of particular interest because ruthenium containing complexes NAMI-A, KP1019, and KP1339 entered clinical trials and DW1/2 is in preclinical levels. The very robust, conformationally rigid organometallic Ru(II) compound DW1/2 is a protein kinase inhibitor and presents new Ru(II) compound designs as anticancer agents. Over the recent years, numerous strategies have been used to encapsulate Ru(II) derived compounds in a nanomaterial system, improving their targeting and delivery into neoplastic cells. A new photodynamic therapy based Ru(II) therapeutic, TLD-1433, has also entered clinical trials. Ru(II)-based compounds can also be photosensitizers for photodynamic therapy, which has proven to be an effective new, alternative, and noninvasive oncotherapy modality.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.7b01689

Cites

113 of 113 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 113 references

Cited by

See all 476

Metadata

Authors
Thota, S., Rodrigues, D. A., Crans, D. C., & Barreiro, E. J.
Venue
Journal of Medicinal Chemistry
Published
2018-02-15
Volume
61
Issue
14
Pages
5805-5821
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2785900358
Cited by
476
References
113
FWCI
19.72
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics? https://app.cochat.ai/papers/10.1021/acs.jmedchem.7b01689
The paper
Thota, S., Rodrigues, D. A., Crans, D. C., & Barreiro, E. J. (2018). Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics? Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.7b01689

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.